New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment.

Hdl Handle:
http://hdl.handle.net/10147/325990
Title:
New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment.
Authors:
Murphy, Kevin P; Kennedy, Marcus P; Barry, Josephine E; O'Regan, Kevin N; Power, Derek G
Affiliation:
Department of Radiology, Cork University Hospital, Ireland.
Citation:
New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment. 2014, 37 (6):351-3 Oncol Res Treat
Journal:
Oncology research and treatment
Issue Date:
2014
URI:
http://hdl.handle.net/10147/325990
DOI:
10.1159/000362614
PubMed ID:
24903767
Abstract:
Ipilimumab, a cytotoxic monoclonal antibody that inhibits cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), has been established as an effective therapy in the management of advanced melanoma. Immune-mediated adverse events are a common side effect.
Item Type:
Article
Language:
en
Keywords:
MELANOMA; IMMUNE DISORDER
ISSN:
2296-5262

Full metadata record

DC FieldValue Language
dc.contributor.authorMurphy, Kevin Pen_GB
dc.contributor.authorKennedy, Marcus Pen_GB
dc.contributor.authorBarry, Josephine Een_GB
dc.contributor.authorO'Regan, Kevin Nen_GB
dc.contributor.authorPower, Derek Gen_GB
dc.date.accessioned2014-09-09T08:19:28Z-
dc.date.available2014-09-09T08:19:28Z-
dc.date.issued2014-
dc.identifier.citationNew-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment. 2014, 37 (6):351-3 Oncol Res Treaten_GB
dc.identifier.issn2296-5262-
dc.identifier.pmid24903767-
dc.identifier.doi10.1159/000362614-
dc.identifier.urihttp://hdl.handle.net/10147/325990-
dc.description.abstractIpilimumab, a cytotoxic monoclonal antibody that inhibits cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), has been established as an effective therapy in the management of advanced melanoma. Immune-mediated adverse events are a common side effect.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to Oncology research and treatmenten_GB
dc.subjectMELANOMAen_GB
dc.subjectIMMUNE DISORDERen_GB
dc.titleNew-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment.en_GB
dc.typeArticleen
dc.contributor.departmentDepartment of Radiology, Cork University Hospital, Ireland.en_GB
dc.identifier.journalOncology research and treatmenten_GB
dc.description.fundingNo fundingen
dc.description.provinceMunsteren
dc.description.peer-reviewpeer-reviewen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.